The Americans for Tax Reform (ATR) informed the Reagan-UDall Foundation in a letter that the US FDA has "seriously and significantly failed" to fulfill its congressional mandate to protect public health.
After months of criticism for its handling of the electronic cigarette review, the Reagan-Udall Foundation is now reviewing the policies and procedures of the FDA's Center for Tobacco Products (CTP). As part of its evaluation, the foundation is providing stakeholders with an opportunity to share their opinions.
In its commentary, ATR suggests seven reforms to enhance the performance of the institution.
The FDA is being urged to incorporate input from interdisciplinary experts, such as those in the fields of psychology and behavioral economics, to increase public awareness and participation in the decision-making process. As promised, the FDA must provide a streamlined pathway for pre-market tobacco applications (PMTA) that is simple and accessible.
The FDA's pre-market application process should prioritize product safety and individual risk rather than behavior and population assessments that can be better collected by a single post-market surveillance team. The FDA should regularly and proactively communicate with all applicants rather than issuing marketing rejections after a year of silence. The agency should consider implementing product standards to streamline the process and look to countries like the UK as a model for effective regulatory systems. The FDA must urgently take action to combat significant public misinformation recognized to exist in the community and serve as an obstacle to smoking cessation. It must reform its approach to addressing adolescent risky behavior and acknowledge that reducing harm can benefit young people while properly assessing the consequences of reducing e-cigarette use among adults and adolescents. Tim Andrews, ATR's director of consumer issues, wrote that the Reagan-Udall Foundation review can help the agency improve its pre-market tobacco review process.
The current pre-market application process for tobacco products is burdening applicants with impossible administrative requirements," he said. "The FDA has failed to notify applicants when the process and requirements change, and reportedly applied different standards to certain applicants. This failure is systemic and our opinion recognizes that these issues cannot be solved by simply increasing funding, especially not by charging user fees to small e-cigarette manufacturers.
Statement:
This article was compiled from third-party information and is intended for industry exchange and learning purposes only.
This article does not represent the viewpoint of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness or accuracy of the content within it. The translation of this article is intended solely for industry communication and research purposes.
Due to the limitations in translation proficiency, the translated article may not fully express the original intended meaning. Please refer to the original text for accuracy.
Regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements or positions, 2FIRSTS is fully aligned with the Chinese government.
The copyright of compiled information belongs to the original media and authors. If there is any infringement, please contact us to have it deleted.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
